RxDoctor Payments Data

Henry Lau, MD

Family Medicine · Gallatin, TNNPI 1750444139

Payments from drug & device makers

$6,958in general payments, 2019–2025

Across 340 payments — averaging $20.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$852
  • AbbVie$624
  • Pfizer$459
  • Mannkind Corporation$262
  • Otsuka America Pharmaceutical, Inc.$242
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,958100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,958 in reported general payments places this provider in the 85th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$136,559
Medicare patients
461
Services billed
15,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$104,819
EliquisApixaban85$96,470
JardianceEmpagliflozin35$42,457
RybelsusSemaglutide22$36,071
XareltoRivaroxaban39$34,299
LinzessLinaclotide16$21,326
MyrbetriqMirabegron18$19,942
MounjaroTirzepatide12$19,119
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$18,199
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,134
FarxigaDapagliflozin Propanediol17$15,853
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$13,568
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$12,567
Gabapentin423$8,152
UbrelvyUbrogepant19$6,943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,851$140,890102 claims
PfizerEliquis$459$96,47085 claims
Boehringer IngelheimJardiance$76$42,45735 claims
Johnson & JohnsonXarelto$92$34,29939 claims
GSKTrelegy Ellipta, Anoro Ellipta$186$31,70250 claims
AbbVieLinzess, Ubrelvy$624$28,26935 claims
Astellas Pharma US IncMyrbetriq$139$19,94218 claims
Lilly USA, LLCMounjaro$224$19,11912 claims
AstraZenecaFarxiga$852$15,85317 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$4,468494 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Gallatin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →